In endometrial cancer and TNBC, there exists crosstalk between the Notch/Hes1 and Wnt/β-catenin pathways, and dual targeting of these pathways represents a potential therapeutic direction (117, 118). This evidence concerns the gene HES1 and endometrial cancer.